Emerging Technology
day one project

Modernizing Radio Spectrum Management

04.05.20 | 1 min read | Text by John Leibovitz & Ruth Milkman

Summary

The Biden-Harris Administration should pursue a set of policies aimed at maximizing productive use of the radio spectrum, a key public good that can be used to create economic and social value. These policies should include adjustments to the institutions that manage the nation’s spectrum; a redefinition of spectrum rights and responsibilities enjoyed by companies that use the spectrum; and options for using the economic value created by spectrum auctions to address persistent public problems.

publications
See all publications
Emerging Technology
day one project
Policy Memo
An Agenda for Ensuring Child Safety in the AI Era

AI is transforming how children learn and live, and policymakers, industry, and educators owe it to the next generation to set in place a responsible policy that embraces this new technology while at the same time ensuring all children’s well-being, privacy, and safety is respected.

01.12.25 | 10 min read
read more
Emerging Technology
day one project
Policy Memo
A Peer Support Service Integrated Into the 988 Lifeline

A peer support option should be integrated into the 988 Suicide and Crisis Lifeline so that 988 service users can choose to connect with specialists based on a shared lived experience.

01.12.25 | 10 min read
read more
Emerging Technology
day one project
Policy Memo
Antitrust in the AI Era: Strengthening Enforcement Against Emerging Anticompetitive Behavior

Given the rapid pace of AI advancement, a proactive effort triumphs over a reactive one. To protect consumers, workers, and the economy more broadly, it is imperative that the FTC and DOJ adapt their enforcement strategies to meet the complexities of the AI era.

01.10.25 | 8 min read
read more
Emerging Technology
day one project
Policy Memo
Clearing the Path for New Uses for Generic Drugs

To encourage greater adoption of generic drugs in clinical practice the FDA should implement a dedicated regulatory pathway for non-manufacturers to seek approval of new indications for repurposed generic drugs.

01.09.25 | 16 min read
read more